NO20070827L - Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. - Google Patents

Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat.

Info

Publication number
NO20070827L
NO20070827L NO20070827A NO20070827A NO20070827L NO 20070827 L NO20070827 L NO 20070827L NO 20070827 A NO20070827 A NO 20070827A NO 20070827 A NO20070827 A NO 20070827A NO 20070827 L NO20070827 L NO 20070827L
Authority
NO
Norway
Prior art keywords
fibrate
platelet aggregation
aggregation inhibitor
cerebral
disorders
Prior art date
Application number
NO20070827A
Other languages
English (en)
Inventor
Jean-Louis Junien
Alan Dunlap Edgar
Michael Wilkins
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of NO20070827L publication Critical patent/NO20070827L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en ny farmasøytisk kombinasjon, inneholdende en inhibitor av blodplateaggregering og et fibrat, hvor inhibitoren av blodplateaggregering fortrinnsvis er enten aspirin eller clopidogrel. En slik farmasøytisk kombinasjon av en inhibitor av blodplateaggregering og et fibrat er forventet å være anvendelige i behandling og/eller forebygging av myokardielt infarkt (hjerteattakk), hjertestans, perifer vaskulær sykdom (omfattende symptomatisk karotidarteriesykdom), kongestiv hjertesvikt, ischemisk hjertesykdom, angina pectoris (omfattende ustabil angina), plutselig hjertedød, ustabil angina, så vel som cerebrovaskulære hendelser så som cerebralt infarkt, cerebral trombose, cerebral, ischemi og transient ischemisk attakk, lidelser relatert til bypass-operasjoner (angioplastikk), tilpasning av endovaskulære proteser og restenose og inflammatoriske lidelser, omfattende artrittiske tilstander så som revmatoid artritt og osteoartritt, så vel som astma eller relaterte luftveis eller respiratoriske inflammatoriske lidelser.
NO20070827A 2004-07-26 2007-02-13 Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. NO20070827L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04291896A EP1621200A1 (en) 2004-07-26 2004-07-26 Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
PCT/EP2005/053603 WO2006010748A1 (en) 2004-07-26 2005-07-25 Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate

Publications (1)

Publication Number Publication Date
NO20070827L true NO20070827L (no) 2007-02-13

Family

ID=34931285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070827A NO20070827L (no) 2004-07-26 2007-02-13 Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat.

Country Status (8)

Country Link
US (1) US20090062240A1 (no)
EP (2) EP1621200A1 (no)
JP (1) JP2008507574A (no)
CN (1) CN1988910A (no)
AU (1) AU2005266310B2 (no)
CA (1) CA2574920A1 (no)
NO (1) NO20070827L (no)
WO (1) WO2006010748A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20075628L (no) * 2005-04-08 2007-11-05 Bgp Products Ireland Ltd Farmasøytiske formuleringer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106912A2 (en) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
FR2932387B1 (fr) 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2010032434A1 (ja) * 2008-09-19 2010-03-25 株式会社アクティバスファーマ 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
CN101984969A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 含有氯吡格雷和贝特类化合物的药物组合物
CN101985038A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 一种用于抗血栓的药物组合物
CN101985042A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 一种用于抗血栓的药物组合物
NZ749230A (en) * 2016-06-28 2023-05-26 Asamedic As Two-component composition
JP6420923B1 (ja) * 2017-04-03 2018-11-07 興和株式会社 医薬
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US6410545B2 (en) * 1998-07-30 2002-06-25 Parker Hughes Institute Lipid lowering quinazoline dietary supplement composition
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001092234A1 (en) * 2000-06-01 2001-12-06 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PT1328266E (pt) * 2000-10-26 2006-05-31 Fournier Lab Ireland Ltd Combinacao de fenofibrato e coenzima q10 para o tratamento de disfuncao endotelial
AU2002302003B2 (en) * 2001-11-28 2008-05-22 Cardanal Pty Ltd Method and system for processing electrocardial signals
WO2008008692A2 (en) * 2006-07-10 2008-01-17 The General Hospital Corporation Method and apparatus for detection and treatment of autonomic system imbalance

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20075628L (no) * 2005-04-08 2007-11-05 Bgp Products Ireland Ltd Farmasøytiske formuleringer
NO343548B1 (no) * 2005-04-08 2019-04-01 Bgp Products Ireland Ltd Farmasøytiske formuleringer

Also Published As

Publication number Publication date
CA2574920A1 (en) 2006-02-02
JP2008507574A (ja) 2008-03-13
EP1778247A1 (en) 2007-05-02
AU2005266310B2 (en) 2011-04-21
AU2005266310A1 (en) 2006-02-02
US20090062240A1 (en) 2009-03-05
EP1621200A1 (en) 2006-02-01
WO2006010748A1 (en) 2006-02-02
CN1988910A (zh) 2007-06-27

Similar Documents

Publication Publication Date Title
NO20070827L (no) Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat.
Bruno et al. Progress in 5H [1] benzopyrano [4, 3-d] pyrimidin-5-amine series: 2-methoxy derivatives effective as antiplatelet agents with analgesic activity
Chowdhury et al. Celecoxib analogs possessing a N-(4-nitrooxybutyl) piperidin-4-yl or N-(4-nitrooxybutyl)-1, 2, 3, 6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies
NO20045557L (no) Kombinasjon av en DPP IV inhibitor og en kardiovaskulaer forbindelse
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
RS51645B (en) 4-FLUORO-N-INDAN-2-ILBENZAMIDE AND ITS USE AS PHARMACEUTICALS
Coy et al. COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2006053082A3 (en) Hydroxybenzoate salts of metanicotine compounds
NO20064295L (no) Bruk av metylenamidderivater i kardiovaskulaere lidelser
WO2007102883A3 (en) Chemical compounds
Bandgar et al. Design, synthesis, characterization and biological evaluation of novel pyrazole integrated benzophenones
NO20090862L (no) 2-fenyl-indoler som prostaglandin D2-reseptorantagonister
DK1513519T3 (da) Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
TNSN04237A1 (en) N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
Chowdhury et al. Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity
JP2002255814A5 (no)
Nam et al. Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors
Abdellatif et al. A diazen-1-ium-1, 2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: Synthesis, biological evaluation and nitric oxide release studies
NO20041732L (no) Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon
ES2314457T3 (es) Asociacion de un antagonista de los receptores tp y de clopidogrel.
DE69010757T2 (de) Phenylalkanolsäureester.
Ezwaie The Beneficial Effects of Aspirin in Cardiovascular Disease Prevention
MY138896A (en) Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application